Oral Oncology Reports最新文献

Epigenetic alterations in oral cancer: Mechanisms, biomarkers, and therapeutic targets 口腔癌的表观遗传学改变：机制、生物标记物和治疗目标

Oral Oncology Reports Pub Date : 2024-10-31 DOI: 10.1016/j.oor.2024.100681

Madhan Krishnan , Sharan Basappa , Shyamaladevi Babu

引用次数: 0

Comparative evaluation of DNA synthesis for qPCR analysis from oral squamous cell carcinoma tissues - A rapid and robust isolation technique for gene expression studies 用于口腔鳞状细胞癌组织 qPCR 分析的 DNA 合成比较评估 - 一种用于基因表达研究的快速、稳健的分离技术

Oral Oncology Reports Pub Date : 2024-10-24 DOI: 10.1016/j.oor.2024.100677

Ramya Mahalingam , Vivek Narayanan , Magesh Karuppur Thiagarajan , T. Jayaprakash , K.V. Leela

{"title":"Comparative evaluation of DNA synthesis for qPCR analysis from oral squamous cell carcinoma tissues - A rapid and robust isolation technique for gene expression studies","authors":"Ramya Mahalingam , Vivek Narayanan , Magesh Karuppur Thiagarajan , T. Jayaprakash , K.V. Leela","doi":"10.1016/j.oor.2024.100677","DOIUrl":"10.1016/j.oor.2024.100677","url":null,"abstract":"<div><h3>Background</h3><div>DNA isolation from biological materials is the initial step in several bioanalytical processes, including the polymerase chain reaction (PCR). This procedure works best with pure DNA devoid of potential amplification reaction inhibitors. Since the quantity and quality of biological samples are limited, it is essential to extract as much DNA as possible from the original sample. The solid-phase extraction technique is frequently used to purify DNA. In this process, the DNA is adsorbed onto a solid support, any contaminants from the reaction are eliminated by washing, and the purified DNA is then eluted from the support. The quality and concentration of DNA have a direct effect on the gene analysis procedure. Therefore, before interpreting the results of PCR-based diagnostic assays, it is imperative to confirm the DNA preparation and integrity, particularly if no pathogenic DNA is identified.</div></div><div><h3>Methods</h3><div>A comparative study was carried out using two standardized protocols for DNA synthesis in comparison with a test protocol incorporating carrier RNA and proteinase K from a viral detection kit. The quality and quantity of the synthesized DNA are assessed by qPCR analysis for gene amplification of metastasis suppressor genes NDRG1, RhoGDI, and KISS 1.</div></div><div><h3>Results and conclusion</h3><div>The test protocol showed higher yields of DNA in comparison to the standard protocol. The concentration of DNA obtained was validated by the concentration of gene expressed from q PCR analysis. The gene expression was significantly higher when the test protocol method was followed for DNA synthesis. Thus the study validates the potential of nucleic acid carrier RNA molecules to improve DNA extraction processes used in tissue samples for gene analysis procedures.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142561289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibition in NPC: A comprehensive review of PD-L1 overexpression and treatment responses 鼻咽癌的免疫检查点抑制：PD-L1过表达和治疗反应综述

Oral Oncology Reports Pub Date : 2024-10-23 DOI: 10.1016/j.oor.2024.100680

Madhan Krishnan , Sharan Basappa , M.V. Vinaya Kumar , Gayathri Sekar

{"title":"Immune checkpoint inhibition in NPC: A comprehensive review of PD-L1 overexpression and treatment responses","authors":"Madhan Krishnan , Sharan Basappa , M.V. Vinaya Kumar , Gayathri Sekar","doi":"10.1016/j.oor.2024.100680","DOIUrl":"10.1016/j.oor.2024.100680","url":null,"abstract":"<div><div>Nasopharyngeal carcinoma (NPC) is a distinct type of cancer that affects the head and neck region, and it is notably linked to infection with the Epstein-Barr Virus (EBV), particularly in endemic regions such as Southeast Asia and Southern China. Despite advances in the conventional care for NPC, including radiation and chemotherapy, the prognosis remains poor for individuals with relapsed or metastatic stages of the disease. Immune checkpoint inhibitors (ICIs), particularly those targeting the PD-1/PD-L1 axis, have emerged as an optimistic therapeutic option. PD-L1 overexpression in NPC contributes to immune avoidance and correlates in relation to these immunotherapies. This review comprehensively explores PD-L1 expression in NPC and its role in tumor immune escape, along with a detailed analysis of clinical trials investigating PD-1/PD-L1 blockade. While PD-L1 overexpression is associated with better responses to ICIs, resistance mechanisms and the complex tumor microenvironment (TME) limit their overall efficacy. We will address these barriers and highlight future directions for improving outcomes, including combination therapies, novel biomarkers, and personalized approaches to treatment. With ongoing research and clinical trials, immune checkpoint inhibition holds great potential to revolutionize NPC therapy, offering hope for improved sustained survival rates and overall well-being for individuals.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142554575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Digitally made nasal prosthesis: A new frontier in facial reconstruction - Case report 数字化鼻假体：面部重建的新领域 - 病例报告

Oral Oncology Reports Pub Date : 2024-10-23 DOI: 10.1016/j.oor.2024.100679

Angel Rose Amalraj, Muthukumar Balasubramanium, Vishal Reddy, Ahila Singaravel Chidambaranathan, Peter John

{"title":"Digitally made nasal prosthesis: A new frontier in facial reconstruction - Case report","authors":"Angel Rose Amalraj, Muthukumar Balasubramanium, Vishal Reddy, Ahila Singaravel Chidambaranathan, Peter John","doi":"10.1016/j.oor.2024.100679","DOIUrl":"10.1016/j.oor.2024.100679","url":null,"abstract":"<div><h3>Background</h3><div>Worldwide, millions of people experience sickness, trauma, or birth defects that negatively impact their social interactions, career, finances, mental health, and overall quality of life. When anatomical portions where plastic surgery is not appropriate or too expensive are given new functions and aesthetics, prostheses improve the quality of life for most affected individuals. The production of prosthesis items could benefit from 3D printing as a viable method to address the drawbacks of traditional construction, including lack of attachment, function, robustness, aesthetics, and cost. But prosthetic material 3D printing is still in its infancy and faces several obstacles, including low mechanical strength in printed parts, printability problems, restricted 3D printing of appropriate prosthesis materials, and flaws.</div></div><div><h3>Case report</h3><div>53 years old male reported with a complaint of a missing nose. The nasal defect was postsurgical following total rhinectomy for squamous cell carcinoma. The patient was treated for Grade 2 squamous cell carcinoma. Patient underwent total rhinectomy and rehabilitated with forehead rotation flap and split thickness graft cover. Then the defect was rehabilitated through digital procedure for creating nasal prosthesis.</div></div><div><h3>Conclusion</h3><div>Digital technology is changing prosthetic design and manufacture by combining precision, personalisation, and efficiency, providing new hope and a higher quality of life for individuals who have had their noses surgically removed.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142554500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral cancer: Recent breakthroughs in pathology and therapeutic approaches 口腔癌：病理学和治疗方法的最新突破

Oral Oncology Reports Pub Date : 2024-10-22 DOI: 10.1016/j.oor.2024.100678

Surekha Ramachandran

引用次数: 0

Journey of Exosomes in Oral Squamous Cell Carcinoma (OSCC) 口腔鳞状细胞癌（OSCC）中的外泌体之旅

Oral Oncology Reports Pub Date : 2024-10-19 DOI: 10.1016/j.oor.2024.100674

Raman Dineja, R. Ashwini

引用次数: 0

Delta Radiomics — Potential role in Head Neck Cancer 德尔塔放射组学--在头颈部癌症中的潜在作用

Oral Oncology Reports Pub Date : 2024-10-19 DOI: 10.1016/j.oor.2024.100676

Shrikant B. Mali

{"title":"Delta Radiomics — Potential role in Head Neck Cancer","authors":"Shrikant B. Mali","doi":"10.1016/j.oor.2024.100676","DOIUrl":"10.1016/j.oor.2024.100676","url":null,"abstract":"<div><h3>Introduction</h3><div>Delta radiomics is a tool used to assess the response of oncologic patients undergoing immunotherapy. It extracts high-dimensional quantitative features from medical images, providing information about cancer's phenotype, genotype, and tumoral microenvironment. This analysis could help avoid invasive procedures and help choose the most suitable therapeutic in multiple therapeutic options. Radiomics has gained interest as an imaging biomarker for predicting response to various immunotherapies. Delta radiomics assesses feature variations from one time point to another based on subsequent images, offering higher value for treatment-outcome prediction or patient stratification into risk categories. It has potential benefits for clinical endpoints in oncology, such as differential diagnosis, prognosis, treatment response prediction, and evaluation of side effects. Further research with prospective and multicentre studies is needed for clinical validation of delta radiomics approaches.</div></div><div><h3>Statement of clinical significance</h3><div>In head and neck oncology, delta radiomics can be used to enhance the precision of diagnosis, assess tumor response, forecast normal tissue toxicity, predict clinical outcome, and pinpoint characteristics for treatment modification. Patients' quality of life may be enhanced by it. It can support post-treatment surveillance. Additionally, it can support the delivery of individualized care based on a patient's reaction to medication and radiation.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142554498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral oncology quality risk management: Tools and strategies to reduce risk 口腔肿瘤学质量风险管理：降低风险的工具和策略

Oral Oncology Reports Pub Date : 2024-10-18 DOI: 10.1016/j.oor.2024.100671

Shweta S. Yamgar , Saee H. Thakur

{"title":"Oral oncology quality risk management: Tools and strategies to reduce risk","authors":"Shweta S. Yamgar , Saee H. Thakur","doi":"10.1016/j.oor.2024.100671","DOIUrl":"10.1016/j.oor.2024.100671","url":null,"abstract":"<div><div>Oral oncology, which addresses the diagnosis and treatment of cancers in the oral cavity, presents unique challenges that demand an effective quality risk management (QRM) framework. This review explores the essential principles of QRM as they relate to oral oncology, focusing on the importance of patient safety and treatment effectiveness amidst complex care processes. The article outlines various tools and methodologies utilized for risk identification and mitigation, including Failure Mode and Effects Analysis (FMEA) and Root Cause Analysis (RCA), while emphasizing the need for standardized protocols to enhance consistency in treatment delivery. Furthermore, it evaluates innovative strategies aimed at increasing patient engagement and improving communication among healthcare providers, which are crucial for successful treatment outcomes. The integration of multidisciplinary teams and advanced technologies is highlighted as a pivotal aspect of QRM in oral oncology. By fostering a culture of continuous improvement and proactive risk management, healthcare stakeholders can better navigate the complexities of oral cancer treatment, ultimately leading to enhanced patient outcomes and safety. This comprehensive examination underscores the vital role of QRM in advancing the quality of care in oral oncology. Oral oncology focuses on diagnosing and treating cancers affecting the oral cavity, including the lips, gums, tongue, and salivary glands. With the rising global incidence of oral cancers, largely attributed to lifestyle factors such as tobacco and alcohol use, the urgency for effective diagnosis and treatment has never been greater. An effective quality risk management (QRM) framework is essential to enhance patient outcomes and safety.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142528984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ectopic primary olfactory neuroblastoma: Clinical management of an extremely rare entity 异位原发性嗅神经母细胞瘤：极其罕见的临床治疗方法

Oral Oncology Reports Pub Date : 2024-10-18 DOI: 10.1016/j.oor.2024.100672

Milena Fior , Francesco Mazzola , Mario Rigante , Joseph Khazen , Renato Covello , Antonello Vidiri , Raul Pellini

{"title":"Ectopic primary olfactory neuroblastoma: Clinical management of an extremely rare entity","authors":"Milena Fior , Francesco Mazzola , Mario Rigante , Joseph Khazen , Renato Covello , Antonello Vidiri , Raul Pellini","doi":"10.1016/j.oor.2024.100672","DOIUrl":"10.1016/j.oor.2024.100672","url":null,"abstract":"<div><h3>Background</h3><div>Olfactory neuroblastoma (ONB) is a rare malignant neoplasm of neuroectodermal origin. Within an already very rare neoplasm, an even rarer and lesser-known entity is ectopic ONB.</div></div><div><h3>Methods</h3><div>A 57-year-old female patient was evaluated for a smooth ethmoidal mass. A contrast-enhanced MRI identified a lesion with epicenter in the osteo-meatal complex without cribriform plate and olfactory recesses involvement. Endoscopic guided biopsy showed ONB Hyams II. An endoscopic trans-nasal resection was performed.</div></div><div><h3>Results</h3><div>The postoperative course was uneventful. A definitive histologic examination confirmed a Hyams grade II, Kadish B ONB, corroborating the ectopic localization. Due to the tumor stage and grade, no adjuvant treatment was performed. The patient was free of disease at one-year postoperative follow-up.</div></div><div><h3>Conclusions</h3><div>Ectopic ONB should be considered in the differential diagnosis of a sinonasal mass. Olfactory bulb and dura resection should be dictated by the clinical or radiological involvement of the cribriform plate.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142528533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic analysis of chemotherapy, immunotherapy, and combination therapy in Head and Neck Squamous Cell Carcinoma (HNSCC) clinical trials: Focusing on overall survival and progression-free survival outcomes 头颈部鳞状细胞癌 (HNSCC) 临床试验中化疗、免疫疗法和综合疗法的系统分析：关注总生存期和无进展生存期结果

Oral Oncology Reports Pub Date : 2024-10-18 DOI: 10.1016/j.oor.2024.100673

Priya Ganesan, Saravanan Sekaran, Pasiyappazham Ramasamy, Dhanraj Ganapathy

{"title":"Systematic analysis of chemotherapy, immunotherapy, and combination therapy in Head and Neck Squamous Cell Carcinoma (HNSCC) clinical trials: Focusing on overall survival and progression-free survival outcomes","authors":"Priya Ganesan, Saravanan Sekaran, Pasiyappazham Ramasamy, Dhanraj Ganapathy","doi":"10.1016/j.oor.2024.100673","DOIUrl":"10.1016/j.oor.2024.100673","url":null,"abstract":"<div><div>Head and neck squamous cell carcinoma (HNSCC) is a challenging malignancy characterized by poor prognosis, particularly in advanced or metastatic stages. Standard chemotherapy, primarily platinum-based, has long been the cornerstone of treatment for recurrent or metastatic HNSCC, yet its survival benefits remain modest, with significant toxicity. The advent of immunotherapy, specifically immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway, has shifted the treatment paradigm by offering durable responses in a subset of patients, particularly those with biomarker-driven indications. Meanwhile, combination therapy, integrating chemotherapy with immunotherapy or targeted agents, has emerged as a potential strategy to enhance therapeutic efficacy. This review provides a comparative analysis of chemotherapy, immunotherapy, and combination therapy (CICT) based on clinical trial outcomes, focusing on two key metrics: overall survival (OS) and progression-free survival (PFS). While chemotherapy alone typically results in limited survival benefits, immunotherapy has demonstrated significant OS improvements, especially in biomarker-selected populations, though its impact on PFS is less consistent. Combination therapies have shown promise in improving both OS and PFS compared to monotherapies, though they also raise concerns about cumulative toxicity. By evaluating the strengths and limitations of each treatment approach, this review aims to clarify their relative roles in the current and future treatment landscape for HNSCC. It also underscores the importance of ongoing research to refine therapeutic strategies and optimize patient outcomes.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142539611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0